Hsbc Holdings PLC grew its holdings in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 47.1% during the second quarter, Holdings Channel reports. The firm owned 3,670 shares of the financial services provider’s stock after purchasing an additional 1,175 shares during the quarter. Hsbc Holdings PLC’s holdings in iShares Biotechnology ETF were worth $504,000 at the end of the most recent quarter.
Several other hedge funds have also made changes to their positions in the business. Future Financial Wealth Managment LLC purchased a new stake in iShares Biotechnology ETF during the 1st quarter worth approximately $27,000. Bbjs Financial Advisors LLC purchased a new position in iShares Biotechnology ETF in the second quarter valued at $31,000. Pacifica Partners Inc. boosted its holdings in iShares Biotechnology ETF by 118.2% in the first quarter. Pacifica Partners Inc. now owns 240 shares of the financial services provider’s stock valued at $33,000 after purchasing an additional 130 shares during the period. YHB Investment Advisors Inc. acquired a new position in iShares Biotechnology ETF during the 1st quarter worth $37,000. Finally, Mather Group LLC. purchased a new stake in iShares Biotechnology ETF during the 1st quarter worth about $57,000. Institutional investors and hedge funds own 62.45% of the company’s stock.
iShares Biotechnology ETF Trading Up 0.5 %
Shares of IBB opened at $145.60 on Tuesday. iShares Biotechnology ETF has a 1 year low of $111.83 and a 1 year high of $150.57. The stock has a 50-day simple moving average of $145.69 and a 200-day simple moving average of $138.91.
iShares Biotechnology ETF Dividend Announcement
iShares Biotechnology ETF Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
See Also
- Five stocks we like better than iShares Biotechnology ETF
- What is the Hang Seng index?
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- How to Effectively Use the MarketBeat Ratings Screener
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- Upcoming IPO Stock Lockup Period, Explained
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.